There is consistent effectiveness in a subset analysis of patients with a baseline FPG <280 mg/dL. In this subgroup of patients, the mean A1c at baseline was 9.0% and the mean FPG level was 211.1 mg/dL. ACTOS compared with placebo achieved significant (P<=0.05) mean A1c reductions of 1.2 percentage points at 15 mg once daily and 2.0 percentage points at 45 mg once daily.
The data are from Study 001, a 26-week, double-blind, placebo-controlled, multicenter study. The subanalysis included 217 patients.

Aronoff S, et al. Diabetes Care. 2000;23:1605-1611.